

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med* 2008;358:2765-75.

Table I. Supplemental information regarding adverse events

	Rivaroxaban	Enoxaparin
	10 mg od	40 mg od
	(n=2209)	(n=2224)
Adverse events during treatment		
Serious adverse events	146 (6.6%)	181 (8.1%)
Total with adverse events*	1369 (62.0%)	1370 (61.6%)
Adverse events leading to treatment discontinuation	85 (3.8%)	100 (4.5%)
Adverse events during treatment with an incidence of ≥3% or difference of ten or more events between any treatment group[†]		
Any event	1413 (64.0%)	1439 (64.7%)
Blood and lymphatic system disorders	107 (4.8%)	105 (4.7%)
Anemia	81 (3.7%)	81 (3.6%)
Cardiac disorders	84 (3.8%)	89 (4.0%)
Bradycardia	7 (0.3%)	17 (0.8%)
Ear and labyrinth disorders	20 (0.9%)	9 (0.4%)
Gastrointestinal disorders	573 (25.9%)	614 (27.6%)
Constipation	148 (6.7%)	178 (8.0%)
Nausea	228 (10.3%)	241 (10.8%)
Vomiting	229 (10.4%)	221 (9.9%)
General disorders and administration-site conditions	400 (18.1%)	375 (16.9%)
Chest pain	15 (0.7%)	29 (1.3%)
Edema peripheral	97 (4.4%)	83 (3.7%)
Pyrexia	247 (11.2%)	233 (10.5%)
Infections and infestations	150 (6.8%)	151 (6.8%)
Injury, poisoning, and procedural complications	377 (17.1%)	356 (16.0%)
Anemia post-operative	113 (5.1%)	108 (4.9%)

Procedural pain	78 (3.5%)	80 (3.6%)
Wound secretion	76 (3.4%)	55 (2.5%)
Investigations	222 (10.0%)	248 (11.2%)
Gamma-glutamyltransferase increased	27 (1.2%)	37 (1.7%)
Hemoglobin decreased	37 (1.7%)	50 (2.2%)
Metabolism and nutrition	50 (2.3%)	68 (3.1%)
Musculoskeletal and connective tissue disorders	133 (6.0%)	123 (5.5%)
Muscle spasms	27 (1.2%)	16 (0.7%)
Nervous system disorders	210 (9.5%)	182 (8.2%)
Dizziness	72 (3.3%)	58 (2.6%)
Headache	55 (2.5%)	45 (2.0%)
Syncope	30 (1.4%)	16 (0.7%)
Psychiatric disorders	160 (7.2%)	155 (7.0%)
Insomnia	87 (3.9%)	94 (4.2%)
Renal and urinary disorders	97 (4.4%)	89 (4.0%)
Dysuria	22 (1.0%)	12 (0.5%)
Respiratory, thoracic, and mediastinal disorders	85 (3.8%)	89 (4.0%)
Cough	14 (0.6%)	24 (1.1%)
Skin and subcutaneous tissue disorders	176 (8.0%)	157 (7.1%)
Blister	31 (1.4%)	14 (0.6%)
Vascular disorders	239 (10.8%)	290 (13.0%)
Deep vein thrombosis	38 (1.7%)	81 (3.6%)
Hypotension	107 (4.8%)	112 (5.0%)

Data are n (%).

*Excluding deep vein thrombosis, pulmonary embolism, and bleeding events

†According to MedDRA, descending total frequency

Figure 1: CONSORT diagram

